Clinical trial · Interventional
Hematopoietic Stem Cell Microtransplantation for in AML
Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia
NCT02676856CI-TRIAL-00030735unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of hematopoietic stem cell microtransplantation for in acute myeloid leukemia (AML)patients who can not receive hematopoietic stem cell transplantation (HSCT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conditioning for CR group | Drug | — | UNRESOLVED |
| Conditioning for Non-CR group | Drug | — | UNRESOLVED |
| hematopoietic stem cell microtransplantation-long-term | Procedure | — | UNRESOLVED |
| hematopoietic stem cell microtransplantation-short-term | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CR group
- description
- For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
- interventionNames
- Procedure: hematopoietic stem cell microtransplantation-long-term
- Drug: Conditioning for CR group
- type
- EXPERIMENTAL
- label
- Non-CR group
- description
- For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
- interventionNames
- Procedure: hematopoietic stem cell microtransplantation-short-term
- Drug: Conditioning for Non-CR group
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * AML patients who have received induction chemotherapy with moderate-high dose Ara-C and 3 courses consolidate chemotherapy * Intolerance or unwillingness of allogeneic HSCT * Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study Exclusion Criteria: * Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * Patients with any conditions not suitable for the trial (investigators' decision)
References
Publications (1)
- BACKGROUNDKong X, Chen Y, Wang LI, Zhou Y, He Y, Nie W, Zhang X, Yin X. Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia. Oncol Lett. 2015 May;9(5):2331-2334. doi: 10.3892/ol.2015.2995. Epub 2015 Feb 27. PMID 26137066